comparemela.com
Home
Live Updates
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival : comparemela.com
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival
Summit Therapeutics Inc. announced the Phase III clinical trial, HARMONI-2 or AK112-303, met its primary endpoint of progression-free survival . HARMONI-2 evaluated monotherapy ivonescimab against...
Related Keywords
China
,
,
Summit Therapeutics Inc
,
Akeso Inc
,
Summit Therapeutics
,
comparemela.com © 2020. All Rights Reserved.